Revenue Breakdown
Composition ()
No data
Revenue Streams
Traws Pharma Inc (TRAW) generates its revenue primarily from Symbio, which accounts for 100.0% of total sales, equivalent to $2.73M. Understanding this concentration is critical for investors evaluating how TRAW navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Traws Pharma Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -376.59%, while the net margin is 595.45%. These profitability ratios, combined with a Return on Equity (ROE) of 7499.20%, provide a clear picture of how effectively TRAW converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TRAW competes directly with industry leaders such as NCEL and BCDA. With a market capitalization of $13.18M, it holds a significant position in the sector. When comparing efficiency, TRAW's gross margin of 100.00% stands against NCEL's N/A and BCDA's N/A. Such benchmarking helps identify whether Traws Pharma Inc is trading at a premium or discount relative to its financial performance.
